Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1988 May;72(2):293–298.

Immunosuppressive effects of (2R,5R)-6-heptyne-2,5-diamine, an inhibitor of polyamine synthesis: II. Beneficial effects on the development of a lupus-like disease in MRL-lpr/lpr mice.

N Claverie 1, J L Pasquali 1, P S Mamont 1, C Danzin 1, M Weil-Bousson 1, M Siat 1
PMCID: PMC1541544  PMID: 3409547

Abstract

(2R,5R)-6-heptyne-2,5-diamine (MAP; MDL 72175), a potent irreversible inhibitor of L-ornithine decarboxylase (ODC), possesses immunosuppressive activities in vitro as the result of inhibition of lymphocyte polyamine biosynthesis. The effects of MAP were now studied in vivo in MRL-lpr/lpr female mice, an animal model for human systemic lupus erythematosus (SLE). Administration of MAP (0.2% in drinking water; drug intake: 0.25-0.35 g/kg body weight/day) to female mice for 15 weeks, starting 8 weeks after birth, reduced by 47% the number of spleen cells, retarded development of lymphadenopathy and, at that time, markedly prolonged the survival of the mice. At week 23, MAP reduced plasma IgG concentrations by 50% whereas, in contrast, those of IgM were elevated 1.5-fold. No statistically significant effects of MAP were observed on plasma levels of anti-DNA autoantibodies although serum anti-RNP and anti-Sm titres tended downwards during treatment. Neither glomerular lesions nor proteinuria were improved by MAP administration. Finally chronic administration of MAP for 45 weeks prolonged the median survival time from 29.75 to 35.5 weeks.

Full text

PDF
296

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andrews B. S., Eisenberg R. A., Theofilopoulos A. N., Izui S., Wilson C. B., McConahey P. J., Murphy E. D., Roths J. B., Dixon F. J. Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. J Exp Med. 1978 Nov 1;148(5):1198–1215. doi: 10.1084/jem.148.5.1198. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Andrews J., Hang L., Theofilopoulos A. N., Dixon F. J. Lack of relationship between serum gp70 levels and the severity of systemic lupus erythematosus in MRL/l mice. J Exp Med. 1986 Feb 1;163(2):458–462. doi: 10.1084/jem.163.2.458. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bartholeyns J., Mamont P., Casara P. Antitumor properties of (2R,5R)-6-heptyne-2,5-diamine, a new potent enzyme-activated irreversible inhibitor of ornithine decarboxylase, in rodents. Cancer Res. 1984 Nov;44(11):4972–4977. [PubMed] [Google Scholar]
  4. Bowlin T. L., McKown B. J., Sunkara P. S. Ornithine decarboxylase induction and polyamine biosynthesis are required for the growth of interleukin-2- and interleukin-3-dependent cell lines. Cell Immunol. 1986 Apr 1;98(2):341–350. doi: 10.1016/0008-8749(86)90294-7. [DOI] [PubMed] [Google Scholar]
  5. Danzin C., Casara P., Claverie N., Metcalf B. W., Jung M. J. (2R,5R)-6-heptyne-2,5-diamine, an extremely potent inhibitor of mammalian ornithine decarboxylase. Biochem Biophys Res Commun. 1983 Oct 14;116(1):237–243. doi: 10.1016/0006-291x(83)90406-0. [DOI] [PubMed] [Google Scholar]
  6. Dixon F. J. ARA Kunkel memorial lecture. Murine lupus. A model for human autoimmunity. Arthritis Rheum. 1985 Oct;28(10):1081–1088. doi: 10.1002/art.1780281002. [DOI] [PubMed] [Google Scholar]
  7. Eisenberg R. A., Winfield J. B., Cohen P. L. Subclass restriction of anti-Sm antibodies in MRL mice. J Immunol. 1982 Nov;129(5):2146–2149. [PubMed] [Google Scholar]
  8. Haegele K. D., Splinter T. A., Romijn J. C., Schechter P. J., Sjoerdsma A. Decarboxylated-S-adenosylmethionine excretion: a biochemical marker of ornithine decarboxylase inhibition by alpha-difluoromethylornithine. Cancer Res. 1987 Feb 1;47(3):890–895. [PubMed] [Google Scholar]
  9. Heby O. Role of polyamines in the control of cell proliferation and differentiation. Differentiation. 1981;19(1):1–20. doi: 10.1111/j.1432-0436.1981.tb01123.x. [DOI] [PubMed] [Google Scholar]
  10. Kelley V. E., Winkelstein A., Izui S., Dixon F. J. Prostaglandin E1 inhibits T-cell proliferation and renal disease in MRL/1 mice. Clin Immunol Immunopathol. 1981 Nov;21(2):190–203. doi: 10.1016/0090-1229(81)90208-7. [DOI] [PubMed] [Google Scholar]
  11. Kolaja G. J., Fast P. E. Renal lesions in MRL mice. Vet Pathol. 1982 Nov;19(6):663–668. doi: 10.1177/030098588201900611. [DOI] [PubMed] [Google Scholar]
  12. Kubo C., Day N. K., Good R. A. Influence of early or late dietary restriction on life span and immunological parameters in MRL/Mp-lpr/lpr mice. Proc Natl Acad Sci U S A. 1984 Sep;81(18):5831–5835. doi: 10.1073/pnas.81.18.5831. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  14. Mamont P. S., Danzin C., Wagner J., Siat M., Joder-Ohlenbusch A. M., Claverie N. Accumulation of decarboxylated S-adenosyl-L-methionine in mammalian cells as a consequence of the inhibition of putrescine biosynthesis. Eur J Biochem. 1982 Apr;123(3):499–504. doi: 10.1111/j.1432-1033.1982.tb06559.x. [DOI] [PubMed] [Google Scholar]
  15. Mamont P. S., Siat M., Joder-Ohlenbusch A. M., Bernhardt A., Casara P. Effects of (2R, 5R)-6-heptyne-2,5-diamine, a potent inhibitor of L-ornithine decarboxylase, on rat hepatoma cells cultured in vitro. Eur J Biochem. 1984 Aug 1;142(3):457–463. doi: 10.1111/j.1432-1033.1984.tb08308.x. [DOI] [PubMed] [Google Scholar]
  16. Pasquali J. L., Mamont P. S., Weryha A., Knapp A. M., Blervaque A., Siat M. Immunosuppressive effects of (2R,5R)-6-heptyne-2,5-diamine an inhibitor of polyamine synthesis: I. Effects on mitogen-induced immunoglobulin production in human cultured lymphocytes. Clin Exp Immunol. 1988 Apr;72(1):141–144. [PMC free article] [PubMed] [Google Scholar]
  17. Pasquali J. L., Urlacher A., Weryha A., Storck D., Mamont P. S. Inhibition by DL-alpha-difluoromethylornithine of the pokeweed mitogen-induced immunoglobulin production in cultured human lymphocytes. Immunopharmacology. 1984 Jun;7(3-4):145–149. doi: 10.1016/0162-3109(84)90030-4. [DOI] [PubMed] [Google Scholar]
  18. Pegg A. E. Recent advances in the biochemistry of polyamines in eukaryotes. Biochem J. 1986 Mar 1;234(2):249–262. doi: 10.1042/bj2340249. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Pisetsky D. S., McCarty G. A., Peters D. V. Mechanisms of autoantibody production in autoimmune MRL mice. J Exp Med. 1980 Nov 1;152(5):1302–1310. doi: 10.1084/jem.152.5.1302. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Seyfried C. E., Morris D. R. Relationship between inhibition of polyamine biosynthesis and DNA replication in activated lymphocytes. Cancer Res. 1979 Dec;39(12):4861–4867. [PubMed] [Google Scholar]
  21. Shaw G. G. Some pharmacological properties of the polyamines spermine and spermidine--a re-appraisal. Arch Int Pharmacodyn Ther. 1972;198(1):36–48. [PubMed] [Google Scholar]
  22. Shiraki M., Fujiwara M. Long term administration of cyclophosphamide into MRL/1 mice. II. The effects on the isotype of anti-DNA antibodies and immunoglobulin secreting cells in the spleen. Clin Exp Immunol. 1984 Mar;55(3):519–524. [PMC free article] [PubMed] [Google Scholar]
  23. Theofilopoulos A. N., Dixon F. J. Etiopathogenesis of murine SLE. Immunol Rev. 1981;55:179–216. doi: 10.1111/j.1600-065x.1981.tb00343.x. [DOI] [PubMed] [Google Scholar]
  24. Wagner J., Hirth Y., Claverie N., Danzin C. A sensitive high-performance liquid chromatographic procedure with fluorometric detection for the analysis of decarboxylated S-adenosylmethionine and analogs in urine samples. Anal Biochem. 1986 May 1;154(2):604–617. doi: 10.1016/0003-2697(86)90036-9. [DOI] [PubMed] [Google Scholar]
  25. Wagner J., Hirth Y., Piriou F., Zakett D., Claverie N., Danzin C. N-Acetyl decarboxylated S-adenosylmethionine, a new metabolite of decarboxylated S-adenosylmethionine: isolation and characterization. Biochem Biophys Res Commun. 1985 Dec 17;133(2):546–553. doi: 10.1016/0006-291x(85)90941-6. [DOI] [PubMed] [Google Scholar]
  26. Wofsy D., Ledbetter J. A., Hendler P. L., Seaman W. E. Treatment of murine lupus with monoclonal anti-T cell antibody. J Immunol. 1985 Feb;134(2):852–857. [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES